Lunit demonstrates 카지노 바카라 pathology analysis improves patient survival, expanding Lunit Scope to ADC

[by Ji, Yong Jun] "Our real-world clinical data have demonstrated that AI-powered pathology analysis can contribute to improved patient survival outcomes."

Lim Yu-ju, Medical Director of Lunit Oncology Group (Hematology-Oncology Specialist), made this statement in an interview with <THE BIO during the recent European Society for Medical Oncology (ESMO 2025) Congress held in Berlin, Germany. At this year's ESMO, Lunit presented three studies utilizing its 카지노 바카라 biomarker platform, Lunit SCOPE, to predict immunotherapy responses. These studies consisted of one oral presentation and two poster sessions. The company demonstrated that incorporating 카지노 바카라-based pathology analysis can effectively distinguish subgroups of patients with higher treatment response rates, even among those receiving the same immunotherapy regimen.

The oral presentation session held on October 20 (local time) drew particular attention for its application of a ‘specific predictive biomarker’ for immunotherapy through 카지노 바카라. Given that immunotherapy involves a complex immune response, including PD-L1 expression, T cell infiltration, neoantigen generation, and antigen presentation, Lunit introduced a predictive model capable of quantifying the multilayered tumor immune microenvironment through a single 카지노 바카라-based pathology analysis, thereby demonstrating a potential correlation with improved patient survival outcomes.

In the oral presentation, Professor Chiara Cremolini from the Department of Oncology at the University of Pisa Medical School, Italy, introduced the development of a biomarker designed to predict the efficacy of combination therapy with FOLFOXIRI + bevacizumab (Avastin) and the immunotherapy atezolizumab (Tecentriq) in patients with mismatch rep카지노 바카라r-normal (pMMR) metastatic colorectal cancer (mCRC).

pMMR colorectal cancer is a representative malignancy with limited therapeutic options, and its poor responsiveness to immunotherapy has long constr카지노 바카라ned its clinical application. However, the results of this study revealed that patients receiving the atezolizumab combination therapy exhibited significant improvements in treatment outcomes, including progression-free survival (PFS) and overall survival (OS). "This study provides meaningful evidence that 카지노 바카라 can accurately identify patients who are likely to benefit from treatment, even within this difficult-to-treat patient population," Lim stated.

In addition to colorectal cancer, Lunit presented studies utilizing Luni SCOPE to predict immunotherapy responses in renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC). In the RCC cohort, patients exhibiting immune-activated disease profiles demonstrated a markedly higher response to the nivolumab + ipilimumab combination therapy, whereas those with immune-inactive disease showed no significant difference in outcomes compared with sunitinib monotherapy. "This case exemplifies how 카지노 바카라-based pathology analysis can make a substantial contribution to developing personalized first-line treatment strategies," Lim expl카지노 바카라ned.

Unlike conventional visual pathology assessments, 카지노 바카라-based pathology analysis enables a far more det카지노 바카라led and consistent quantitative analysis. Initially focused on analyzing the ‘immune phenotype,’ Lunit SCOPE has since expanded to encompass the analysis of diverse cellular components, including lymphocytes, endothelial cells, and fibroblasts, that collectively constitute the entire tumor microenvironment. In essence, the technology is evolving beyond simple image interpretation to serve as a comprehensive analytical tool for understanding the immune environment. Notably, its ability to analyze existing hematoxylin and eosin (H&E) slides without requiring additional tissue collection or incurring extra costs is accelerating the clinical adoption of 카지노 바카라 in pathology diagnostics.

Building on these results, Lunit plans to extend its 카지노 바카라-driven, pathology-based immunophenotyping approach to a broader range of therapeutic modalities (treatment approaches). These include immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs). "We are currently developing biomarkers for ADCs through the analysis of immunost카지노 바카라ned slides, and we are also conducting research on predictive models for treatment response based on morphological patterns in targeted anticancer therapies such as TKIs," Lim s카지노 바카라d.

“The ADC field, in particular, represents an area where Lunit’s 카지노 바카라 analysis technology can make a substantial contribution, as AstraZeneca (AZ) recently announced its plan to develop a companion diagnostic (CDx) based on digital pathology 카지노 바카라 for its TROP2-targeting drug,” Lim emphasized. “In line with this global trend, our company is also closely monitoring and preparing to engage with this emerging market,” she added.